investing
'Buy low, sell high' is just the tip of the iceberg; learn the art of investing from expert traders and how to make your money grow.
RPM International Inc Increases Dividend As Fundamentals Recover
It was another very light week for financial statement filings as companies with fiscal quarters ended August passed their deadline. The larger volume of companies with begin to appear this week and peak on November 8. The election result will not be the only reveal in November.
Jacob WolinskyPublished 2 years ago in Trader
Mobius Interactive Ltd., AffPapa Announce Collaboration to Facilitate Process of Finding Partners, Overcome Challenges
AffPapa’s dedication to mission provides opportunities to broaden operator base, offer best services Mobius has already entered iGaming, eSports sectors with three differentiated brand offerings and hundreds of joint ventures with VIP and Master gaming affiliates
InvestorBrandNetworkPublished 2 years ago in Trader
Pac Roots Cannabis Corp. (PACR) Set to Benefit as Hemp and Cannabis Producers Evolve, Differentiate Crop Cultivation
Following its tie-up with Phenome One Corp, Pac Roots offers over 350 meticulously designed cultivars possessing wide array of characteristics Introduction of patent protection on genetically modified hemp strains along with insurance provided to hemp growers incentivizes hemp production, drives greater demand for genetically modified seeds and cultivars
InvestorBrandNetworkPublished 2 years ago in Trader
SRAX Inc. (NASDAQ: SRAX) Spinoff BIGtoken(R) Inc. Announces George Stella as Chief Revenue Officer
SRAX moving BIGtoken to separate publicly traded company through definitive share exchange agreement with Force Protection Video Equipment Corp BIGtoken platform compensates over 16 million users for data that marketers access for fee
InvestorBrandNetworkPublished 2 years ago in Trader
180 Life Sciences Corp. Expands IP Portfolio with EU, U.S., and Chinese Patents
180 Life Sciences is in the final stages of its merger process with KBL Merger Corp. IV, with the resulting entity to list on NASDAQ under the ticker “ATNF” The company is devoting its clinical-stage biotechnology research to producing solutions that will help battle inflammation. Its primary focus is to treat fibrosis and inflammation using anti-TNF therapy The estimated annual market size for anti-inflammatory therapeutics is projected to grow to an estimated $106.1 billion in 2020.
InvestorBrandNetworkPublished 2 years ago in Trader
FinovateWest Digital 2020: Discover Tomorrow’s Solutions to Today’s Fintech Challenges
Finovate West Digital is on. Taking the place of Finovate Spring 2020, the event, set for Nov. 23–25, 2020, retains all the promise of its vernal antecedent. Although it is now a completely virtual affair, the conference maintains its merit as a platform to provide a rewarding combination of education, information and networking.
InvestorBrandNetworkPublished 2 years ago in Trader
Net Element Inc. (NASDAQ: NETE) Well-Poised to Capitalize as EV Market Set to Grow by 29% per Annum Over Next Decade
Mullen expects to begin marketing Dragonfly K50, sold in conjunction with JV partner Qiantu Motors from 2Q2021 followed by its own EV SUV in 2022 Deloitte expects annual EV sales to rise from 2.5mn in 2020 to 31.1mn in 2030, implying 29% CAGR over next ten years By 2030, EVs expected to account for 32% of all automobile sales globally, approximately 27% in United States
InvestorBrandNetworkPublished 2 years ago in Trader
AzurRx BioPharma Inc. (NASDAQ: AZRX) is “One to Watch”
AzurRx BioPharma’s lead therapeutic, MS1819, is a recombinant lipase treatment for exocrine pancreatic insufficiency and is currently targeting patients with cystic fibrosis and chronic pancreatitis – an established global market of more than $2 billion The company is currently pursuing parallel monotherapy and combination therapy trials, which are anticipated to produce topline data in Q1 2021 and Q2 2021, respectively Previously completed clinical trials of MS1819 showed primary and secondary endpoint efficacy, with a positive safety profile To fully finance its ongoing Phase 2 trials and being preparations for a pivotal Phase 3 study in 2021, as well as to fund current operations, the company raised gross cash capital of $22.1 million as of July 2020 AzurRx is determined to develop MS1819 as a safer alternative to porcine pancreatic enzyme replacement therapy, significantly reducing the pill burden of cystic fibrosis patients
InvestorBrandNetworkPublished 2 years ago in Trader
Sharing Services Global Corp. (SHRG) in Ideal Position to Benefit as Direct-Sales Industry Posts Healthy Growth
Wellness continues to be leader in U.S. space, where SHRG continues to attract customers, entrepreneurs with inclusive Blue Ocean strategy Strategy proves successful as reflected in robust fundamentals SHRG continues to post
InvestorBrandNetworkPublished 2 years ago in Trader
ESG Investing Support Services-Riding the Trend
ESG investing is one of the fastest-growing trends in the investment world. Asset Managers are moving towards ESG investing at a great pace, not only due to regulatory compliance requirements but also because ESG investing has been proven to show better returns and alpha in the past.
Prabhash ChoudharyPublished 2 years ago in Trader
CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Takes Another Step Closer to Q1 Launch of Brain Cancer Drug Trial
The company is working to build on promising results from a 2006 Phase I trial, which provided 44 percent of its limited patient pool with clinically significant improvement in disease stability and one patient with a durable complete response (no evidence of any tumor remaining) for over 14 years CNS Pharmaceuticals expects to launch a pivotal Phase II trial of Berubicin at the beginning of next year and has been assembling a team of partner companies help with the trial CNS recently announced that the partner contracted to manufacture the Active Pharmaceutical Ingredient (API) for Berubicin has received a Certificate of Analysis necessary for the drug substance to be used in the clinical trial The company is also preparing in collaboration with its sub licensed partner, WPD Pharmaceuticals, for the first Phase I pediatric trial of Berubicin CNS is continuing the pre-clinical development of the company’s second promising cancer-fighting drug candidate, WP1244
InvestorBrandNetworkPublished 2 years ago in Trader
Predictive Oncology Inc. (NASDAQ: POAI) CEO Schwartz Pens Letter to Shareholders, Elaborates on Ongoing Company Developments
Schwartz elaborated on various developments within each of POAI’s divisions, has reiterated his optimism on company’s operations going forward CEO also revealed that company’s revenue trends have stabilized and are now on upward trend with cash burn beginning to decline Company also revealed its ability to access over $10 million in undrawn equity lines of credit
InvestorBrandNetworkPublished 2 years ago in Trader
